Effect of Labetalol for Treating Patients with Pregnancy-Induced Hypertension: A Systematic Review

被引：0
作者：
Bej, Punyatoya [1 ]
Das, Sambhunath [2 ]
机构：
[1] Rama Med Coll & Res Ctr, Dept Community Med, Hapur, Uttar Pradesh, India
[2] All India Inst Med Sci, Dept Cardiac Anaesthesia, New Delhi, India
来源：
JOURNAL OF THE PRACTICE OF CARDIOVASCULAR SCIENCES | 2022年 / 8卷 / 03期
关键词：
Eclampsia; fetal outcome; labetalol; maternal outcome; nifedipine; preeclampsia; pregnancy-induced hypertension; ORAL NIFEDIPINE; INTRAVENOUS LABETALOL; ANTIHYPERTENSIVE TREATMENT; BLOOD-PRESSURE; HYDRALAZINE; METHYLDOPA; EMERGENCY; TRIAL;
D O I：
10.4103/jpcs.jpcs_69_22
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Pregnancy-induced hypertension (PIH) is one of the main causes of maternal mortality. Many first- and second-line drugs are available to treat the condition. Labetalol lowers blood pressure by blocking both alpha and beta adrenergic receptors. It preserves uteroplacental blood flow efficiently. A systemic review was carried out to find the efficacy and safety of labetalol in the treatment of PIH. Three thousand twenty-six studies were retrieved in 20 years. Finally, 28 studies were selected after applying the review criteria. Twenty-three studies detected that labetalol had superior or similar action compared to other drugs in controlling hypertension in patients with preeclampsia and eclampsia. The systematic review concluded that labetalol is a safe, effective, first-choice of drug with few side effects in treating PIH.
引用
收藏
页码：144 / 151
页数：8
相关论文
共 50 条
  • [31] Acute Antihypertensive Therapy in Pregnancy-Induced Hypertension: Is Nicardipine the Answer?
    Vadhera, Rakesh B.
    Pacheco, Luis D.
    Hankins, Gary D. V.
    AMERICAN JOURNAL OF PERINATOLOGY, 2009, 26 (07) : 495 - 499
  • [32] CLDN3 expression and function in pregnancy-induced hypertension
    Zhao, Aixin
    Qi, Yunfang
    Liu, Kun
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2020, 20 (04) : 3798 - 3806
  • [33] Prevalence of vitamin D deficiency in Egyptian patients with pregnancy-induced hypertension
    Osman, Omneya M.
    Gaafar, Tagrid
    Eissa, Tamer S.
    Abdella, Rana
    Ebrashy, Alaa
    Ellithy, Ahmed
    JOURNAL OF PERINATAL MEDICINE, 2020, 48 (06) : 583 - 588
  • [34] Impact of pregnancy-induced hypertension on fetal growth
    Xiong, X
    Mayes, D
    Demianczuk, N
    Olson, DM
    Davidge, ST
    Newburn-Cook, C
    Saunders, LD
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1999, 180 (01) : 207 - 213
  • [35] THE ASSOCIATION OF PREGNANCY-INDUCED HYPERTENSION AND UTERINE MALFORMATIONS
    BENRAFAEL, Z
    SEIDMAN, DS
    RECABI, K
    SERR, DM
    MASHIACH, S
    GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 1990, 30 (02) : 101 - 104
  • [36] HISTORY OF MIGRAINE AND RISK OF PREGNANCY-INDUCED HYPERTENSION
    MARCOUX, S
    BERUBE, S
    BRISSON, J
    FABIA, J
    EPIDEMIOLOGY, 1992, 3 (01) : 53 - 56
  • [37] Association of insulin resistance and autonomic tone in patients with pregnancy-induced hypertension
    Guo, Jing
    Liu, Guanghui
    Guo, Gang
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 2018, 40 (05) : 476 - 480
  • [38] Changes in capillary diameters in pregnancy-induced hypertension
    Rusavy, Zdenek
    Pitrova, Barbora
    Korecko, Vladimir
    Kalis, Vladimir
    HYPERTENSION IN PREGNANCY, 2015, 34 (03) : 307 - 313
  • [39] Pathophysiology of placentation abnormalities in pregnancy-induced hypertension
    Furuya, Mitsuko
    Ishida, Junji
    Aoki, Ichiro
    Fukamizu, Akiyoshi
    VASCULAR HEALTH AND RISK MANAGEMENT, 2008, 4 (06) : 1301 - 1313
  • [40] ATRIAL-NATRIURETIC-FACTOR IN PREGNANCY AND PREGNANCY-INDUCED HYPERTENSION
    FOURNIER, A
    GREGOIRE, I
    ELESPER, N
    LALAU, JD
    WESTEEL, PF
    MAKDASSI, R
    FIEVET, P
    DEBOLD, AJ
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1991, 69 (10) : 1601 - 1608
12345